| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 1,330 | 1,260 | 1,200 | 1,390 |
| Sales Growth | -100.00% | +5.56% | +5.00% | -13.67% | +0.72% |
| Net Income | -18,260 | -7,900 | -16,710 | -11,930 | -9,090 |
| Net Income Growth | -131.14% | +52.72% | -40.07% | -31.24% | +28.31% |
Avalon Globocare (ALBT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Avalon GloboCare Corp. is a clinical-stage biotechnology company. It involved in developing and delivering innovative, transformative cellular therapeutics, precision diagnostics and clinical laboratory services. Avalon GloboCare Corp. is based in FREEHOLD, N.J.